FR2910811B1 - Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments - Google Patents

Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments

Info

Publication number
FR2910811B1
FR2910811B1 FR0700018A FR0700018A FR2910811B1 FR 2910811 B1 FR2910811 B1 FR 2910811B1 FR 0700018 A FR0700018 A FR 0700018A FR 0700018 A FR0700018 A FR 0700018A FR 2910811 B1 FR2910811 B1 FR 2910811B1
Authority
FR
France
Prior art keywords
riluzole
derivatives
new drugs
manufacturing new
manufacturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0700018A
Other languages
English (en)
Other versions
FR2910811A1 (fr
Inventor
Ammar Achour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMMAR ACHOUR, FR
Original Assignee
ASS POUR LE DEV de la BIOTHERA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASS POUR LE DEV de la BIOTHERA filed Critical ASS POUR LE DEV de la BIOTHERA
Priority to FR0700018A priority Critical patent/FR2910811B1/fr
Priority to PCT/FR2007/002186 priority patent/WO2008096081A2/fr
Priority to US12/448,743 priority patent/US20100093655A1/en
Priority to EP07872459A priority patent/EP2114400A2/fr
Priority to CA002674014A priority patent/CA2674014A1/fr
Publication of FR2910811A1 publication Critical patent/FR2910811A1/fr
Application granted granted Critical
Publication of FR2910811B1 publication Critical patent/FR2910811B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0700018A 2007-01-03 2007-01-03 Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments Active FR2910811B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0700018A FR2910811B1 (fr) 2007-01-03 2007-01-03 Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
PCT/FR2007/002186 WO2008096081A2 (fr) 2007-01-03 2007-12-28 Utilisation du riluzole et de ses dérivés pour fabriquer de nouveaux médicaments
US12/448,743 US20100093655A1 (en) 2007-01-03 2007-12-28 Use of riluzole and derivatives thereof for producing new drugs
EP07872459A EP2114400A2 (fr) 2007-01-03 2007-12-28 Utilisation du riluzole et de ses dérivés pour fabriquer de nouveaux médicaments
CA002674014A CA2674014A1 (fr) 2007-01-03 2007-12-28 Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0700018A FR2910811B1 (fr) 2007-01-03 2007-01-03 Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments

Publications (2)

Publication Number Publication Date
FR2910811A1 FR2910811A1 (fr) 2008-07-04
FR2910811B1 true FR2910811B1 (fr) 2009-07-10

Family

ID=38109622

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0700018A Active FR2910811B1 (fr) 2007-01-03 2007-01-03 Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments

Country Status (5)

Country Link
US (1) US20100093655A1 (fr)
EP (1) EP2114400A2 (fr)
CA (1) CA2674014A1 (fr)
FR (1) FR2910811B1 (fr)
WO (1) WO2008096081A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031707A1 (fr) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine et leurs procédés d'utilisation
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
EP1002535A1 (fr) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou Nouvelle utilisation des antagonistes du glutamate pour le traitement du cancer
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease

Also Published As

Publication number Publication date
US20100093655A1 (en) 2010-04-15
CA2674014A1 (fr) 2008-08-14
FR2910811A1 (fr) 2008-07-04
EP2114400A2 (fr) 2009-11-11
WO2008096081A2 (fr) 2008-08-14
WO2008096081A3 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
CY2020008I2 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
CY2020011I1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
LTPA2015040I1 (lt) Vaistų farmakokinetinių savybių moduliatoriai
BRPI0719840A2 (pt) Formas de dosagem de películas não-mucoadesiva
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
DK2151438T3 (da) Lægemiddel indeholdende PPAR-Deltaagonist
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2399580T3 (da) Farmaceutiske doseringsformer
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
DE06722936T8 (de) Isomerisation pharmazeutischer zwischenprodukte
BRPI0719394A2 (pt) Preparação medicinal sólida
DK2018158T3 (da) Ny racecadotril administrationsform
BRPI0813100A2 (pt) Preparação sólida farmacêutica e método de produção da mesma
FI20070808A0 (fi) GDNF:n silmukointivariantit ja niiden käytöt
BRPI0818702A2 (pt) Formulação farmacêutica de ácido clavulânico
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
FR2910811B1 (fr) Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
BRPI0810168A2 (pt) Composições farmacêuticas de bissulfato de clopidogrel e processos de preparação das mesmas
FR2912654B1 (fr) Association medicamenteuse comprenant du phloroglucinol et du paracetamol
FI20086024A0 (fi) Uusi farmaseuttinen tuote
FR2907784B1 (fr) Derives phenyliques et leur utilisation comme medicament
FR2955495B1 (fr) Medicament pour la reduction de la cholesterolemie
TH0701005810A (th) การตั้งสูตรตำรับยาทาภายนอกและวิธีการใช้
FI20095511A0 (fi) Lääkeaineen uusi käyttö
TH107945B (th) สารอนุพันธ์ 1,3-ไดไฮโดร-2H-ไพร์โรโล[3,2-b]ไพริดิน-2-โอน, การเตรียมสารเหล่านี้ และการประยุกต์ใช้ทางการบำบัดรักษาของสารเหล่านี้

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

TP Transmission of property

Owner name: AMMAR ACHOUR, FR

Effective date: 20170208

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17